Interview: AC Immune CEO Reflects On Alzheimer's R&D Post-CREAD
Executive Summary
The recent failure of the CREAD studies to show a therapeutic effect for crenezumab in Alzheimer’s disease stunned developers. However, an ongoing clinical study of the MAb, and a series of other innovations being explored at Switzerland’s AC Immune, might still provide answers to this intractable condition.
You may also be interested in...
South Korea's ADEL Innovates With Anti-Tau Antibody For Alzheimer’s Disease
Emerging Company Profile: ADEL Inc. CEO Seung-Yong Yoon tells Scrip how its anti-tau antibody brings something different to the table in the challenging field of Alzheimer's disease and what's in store for the South Korean bioventure.
Rx Spending Growth To Be Driven By New Drug Entries, CMS Says
Advances in cancer, diabetes, and Alzheimer's could lead to expensive new treatments, contributing to spending increases in next decade, according to CMS projections.
AC Immune/Roche Drop Crenezumab After Phase III CREAD Alzheimer's Failure
Interim top-line data from CREAD 1 and 2 indicate crenezeumab is unlikely to meet its primary endpoints and the studies are being stopped, but a clinical study in Colombia in familial Alzheimer’s is set to continue.